Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the ‘Central neuropathic pain in adults’ indication extension.
Clinical Benefit
| Substantial |
The actual benefit of LYRICA in the treatment of central neuropathic pain in adults is substantial. |
Clinical Added Value
| no clinical added value |
Lyrica does not provide any improvement in actual benefit (IAB level V) over the usual management of central neuropathic pain in adults. |
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
VSxaF6bVzUg2S9HG
